Full text is available at the source.
Abstract
The Cardiometabolic Disease Staging (CMDS) model was used to evaluate changes in cardiometabolic risk related to COVID-19 infection.
- Changes in cardiometabolic risk may be linked to the development of Long COVID.
- The CMDS model quantitatively measures the severity of cardiometabolic disease.
- COVID-19 infection could alter cardiometabolic risk profiles in affected individuals.
- Observations suggest a potential relationship between cardiometabolic risk and Long COVID outcomes.
Simplified